Hartland,

As for the timing of the futility analysis and it's potential relation to the LOI, I honestly don't know what to think right now. We are now being told that instead of the futility analysis happening at 50% of events, it may happen anywhere in the 50% to 75% of events range, depending upon the outcome ongoing discussions between the DSMB and Clinical Steering Committee. Based on the previous sentence, they may or may not already be past 50% of events. We know there are changes coming to BETonMACE due to the FDA granting approval to include US patients, but the details of how this affects enrollment number, enrollment rate, target MACE events, and timelines is unknown. The latest financing only yields a couple months of funds at their current burn rate, but the loan maturity date has been extended to the end of December. They have a renal trial with an anticipated start date of September 15th and a Fabry disease trial with an anticipated start date of October 30th, but how are they going to pay for these? We haven't had a webcast in 9 months. The slide decks posted from non webcast investor conferences have had very little new info since December. We've been teased with a new website coming for several months now. We've had a mysterious scheduling conflict causing cancelation of Rodman and Renshaw investor conference attendance. We've been told over and over of new analysts coming on board but no analyst reports have materialized. And now we have a news release indicating a letter of intent is in hand for a regional licensing deal and/or significant equity investment and that management is diligently pursuing this opportunity. 

So to answer your question.....your guess is as good as mine. 

BearDownAZ